News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week in Review: Zhejiang Medicine to Develop Ambrx, Inc. Breast Cancer Drug



6/24/2013 9:15:20 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

June 22, 2013 --Zhejiang Medicine Co. will collaborate with Ambrx of San Diego to develop an Ambrx molecule that targets Her2-positive breast cancer; Suzhou Ribo Life Sciences acquired China Rights to Life Technologies’ Invivofectamine® Rx delivery technology for siRNA therapeutics; Shanxi CY Pharma announced plans to purchase a stake of at least 80% in Hangzhou Baoling Group Co., Ltd.; BioClinica®, a clinical trial services company headquartered in the US, formed a cardiac safety partnership with TEDA International Cardiovascular Hospital in Tianjin; Sichuan BoXin LaiTe Biotechnology signed a MOU to advance drug development projects with the University of British Columbia; and China’s chief drug safety regulator, the CFDA, felt compelled to have a meeting with Johnson & Johnson about product recalls. More details….

Stock Symbols: (SHA: 600216) (NSDQ: LIFE) (SHE: 300254) (NYSE: JNJ)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES